Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference

About this update from Helix Biopharma Corp.

[{"type":"text","content":"\n\n\n\nAURORA, Ontario, June 19 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: HBP)\ntoday announced that Dr. Heman Chao, chief scientific officer at Helix\nBioPharma Corp., will be presenting a scientific poster describing L-DOS47\nanalytical method development findings at the 2009 American Association of\nPharmaceutical Scientists ("AAPS") National Biotechnology Conference, which\nruns from June 21st to 24th at the Washington State Convention and Trade\nCenter in Seattle, Washington.\n\n\nThe conference is a premier gathering of pharmaceutical and\nbiopharmaceutical scientists addressing all areas of the manufacturing,\nnon-clinical testing, clinical testing and regulatory treatment of established\nand emerging drug compounds.\n\n\nThe poster, entitled "Analytical Method Development for L-DOS47, a Novel\nCandidate for the Treatment of Lung Adenocarcinoma" provides a summary of the\nanalytical methods which have been developed to characterize the\nconcentration, identity, purity, enzymatic activity, and potency of lots of\nL-DOS47 drug substance and drug product. The work presented demonstrates that\nanalytical methods have been successfully developed to support the\nmanufacture, release and subsequent stability testing of GMP batches of\nL-DOS47 as Helix progresses towards initiating clinical testing with the\nproduct. Accompanying Dr. Chao for the poster presentation will be Dr. Juan\nDavagnino, associate director, biopharmaceutical development at KBI Biopharma;\nHelix's U.S.-based, third-party contract service provider responsible for\nassisting Helix in developing and executing the necessary quality control and\nstability testing programs for L-DOS47 drug substance and drug product lots.\n\n\nA copy of the poster is available on Helix's website for download at\nhttp://www.helixbiopharma.com.\n\n\nFor additional information on the 2009 AAPS National Biotechnology\nConference, please visit\nhttp://www.aapspharmaceutica.com/meetings/biotec/bt09/index.asp.\n\n\n\n\nAbout L-DOS47\n\n\nL-DOS47 combines Helix's proprietary DOS47 new drug candidate with a\nhighly specific single domain antibody, to form a potential new targeted drug\nproduct for the treatment of adenocarcinoma of the lung, the most common form\nof lung cancer in the world today. L-DOS47 is thought to function by\nleveraging a natural process in the ...

More updates from Helix Biopharma Corp.